Journal of Psychopharmacology
May 12, 2026
Pravesh Sharma, Jared Kendrick, Jennifer Schram et al.
BACKGROUND: Preliminary evidence examining ibogaine in neuropsychiatric and substance use disorders is accumulating. As patient interest and off-label use grow, clinicians require an understanding of emerging dosing strategies, investigational protocols, and reported adverse effects to appropriately counsel patients and contextualize potential risks and benefits. METHODS: Databases were...
Behavioral Sciences
March 24, 2026
J. Richard Kendrick, Ghonwa Ahmad, Audrey Wood et al.
The use of ketamine for the management of neuropsychiatric conditions outside clinical settings has rapidly expanded, creating a critical need to understand diverse individual experiences. We conducted a qualitative content analysis of posts from the r/TherapeuticKetamine subreddit. From 3302 threads, the 500 highest-engagement threads (12,852 comments) were analyzed by independent coders...
Substance Use & Misuse
2025
Jadyn Hartwig, Jared Kendrick, Ghonwa Ahmad et al.
3 citations
Background: Amanita muscaria, commonly known as fly agaric or fly amanita, is a mushroom renowned for its distinctive appearance and psychoactive properties attributed to its compounds, ibotenic acid, and muscimol. Contemporary interest in Amanita muscaria has surged, driven by anecdotal reports of perceived psychological and medicinal benefits. Objectives: However, no clinical studies exist...
Journal of Psychopharmacology
August 31, 2023
Pravesh Sharma, Quang Anh Nguyen, Erin Carpenter et al.
32 citations
Hallucinogenic mushrooms have been used in religious and cultural ceremonies for centuries. Of late, psilocybin, the psychoactive compound in hallucinogenic mushrooms, has received increased public interest as a novel drug for treating mood and substance use disorders (SUDs). In addition, in recent years, some states in the United States have legalized psilocybin for medical and recreational...
Substance Use & Misuse
August 17, 2021
Pravesh Sharma, Kira E. Riehm, Andrea S. Young et al.
3 citations
Background: Adolescent cannabis use is an established risk factor for the development of psychosis, but the premorbid vulnerability factors and specificity versus generality of the psychotic symptom domains affected in cannabis-psychosis relationships remain incompletely understood. To improve our understanding of these relationships, we used longitudinal data to examine the individual and...